Martin E Gore
Overview
Explore the profile of Martin E Gore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
4205
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kelderman S, Heemskerk B, van Tinteren H, van den Brom R, Hospers G, van den Eertwegh A, et al.
Cancer Immunol Immunother
. 2014 Mar;
63(5):449-58.
PMID: 24609989
Introduction: Ipilimumab, a cytotoxic T lymphocyte-associated antigen-4 blocking antibody, has improved overall survival (OS) in metastatic melanoma in phase III trials. However, about 80 % of patients fail to respond,...
12.
Ang J, Gourley C, Powell C, High H, Shapira-Frommer R, Castonguay V, et al.
Clin Cancer Res
. 2013 Aug;
19(19):5485-93.
PMID: 23922302
Purpose: Preclinical data suggest that exposure to PARP inhibitors (PARPi) may compromise benefit to subsequent chemotherapy, particularly platinum-based regimens, in patients with BRCA1/2 mutation carrier ovarian cancer (PBMCOC), possibly through...
13.
Motzer R, Escudier B, Tomczak P, Hutson T, Michaelson M, Negrier S, et al.
Lancet Oncol
. 2013 Apr;
14(6):552-62.
PMID: 23598172
Background: In a phase 3 trial comparing the efficacy and safety of axitinib versus sorafenib as second-line treatment for metastatic renal cell carcinoma, patients given axitinib had a longer progression-free...
14.
Khattak M, Bakr F, Krzystanek M, Szallasi Z, Gerlinger M, Santos C, et al.
J Clin Oncol
. 2013 Jan;
31(7):971-2.
PMID: 23295806
No abstract available.
15.
Tan D, Yap T, Hutka M, Roxburgh P, Ang J, Banerjee S, et al.
Eur J Cancer
. 2012 Dec;
49(6):1246-53.
PMID: 23265709
Introduction: Preclinical data suggest that BRCA1 and BRCA2 (BRCA1/2)-mutated ovarian cancers (BMOC) are exquisitely sensitive to platinum-salts, but resistant to microtubule-stabilizing anticancer agents. The clinical relevance of these preclinical data...
16.
Khattak M, Fisher R, Pickering L, Gore M, Larkin J
BJU Int
. 2012 Sep;
110(10):1407-8.
PMID: 22937754
No abstract available.
17.
Karapanagiotou E, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, et al.
Clin Cancer Res
. 2012 Feb;
18(7):2080-9.
PMID: 22316603
Purpose: Reovirus type 3 Dearing (RT3D) replicates preferentially in Ras-activated cancers. RT3D shows synergistic in vitro cytotoxicity in combination with platins and taxanes. The purpose of this phase I/II study...
18.
Mulders P, Hawkins R, Nathan P, de Jong I, Osanto S, Porfiri E, et al.
Eur J Cancer
. 2012 Jan;
48(4):527-37.
PMID: 22285180
Background: Cediranib is a highly potent vascular endothelial growth factor (VEGF) signalling inhibitor with activity against VEGF receptors 1, 2 and 3. This Phase II, randomised, double-blind, parallel-group study compared...
19.
Bolton K, Chenevix-Trench G, Goh C, Sadetzki S, Ramus S, Karlan B, et al.
JAMA
. 2012 Jan;
307(4):382-90.
PMID: 22274685
Context: Approximately 10% of women with invasive epithelial ovarian cancer (EOC) carry deleterious germline mutations in BRCA1 or BRCA2. A recent article suggested that BRCA2-related EOC was associated with an...
20.
Rini B, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson T, et al.
Lancet
. 2011 Nov;
378(9807):1931-9.
PMID: 22056247
Background: The treatment of advanced renal cell carcinoma has been revolutionised by targeted therapy with drugs that block angiogenesis. So far, no phase 3 randomised trials comparing the effectiveness of...